Research Paper Volume 13, Issue 4 pp 6055—6065

miR-29b restrains cholangiocarcinoma progression by relieving DNMT3B-mediated repression of CDKN2B expression

class="figure-viewer-img"

Figure 1. miR-29b downregulation is associated with poor overall survival in cholangiocarcinoma. (A) Relative miR-29b expression in 30 patients with cholangiocarcinoma after normalization to adjacent, normal tissue expression (B) miR-29b expression data for 30 cholangiocarcinoma and 20 non-tumor specimens. (C) Kaplan-Meier curves for cholangiocarcinoma patients with low and high expression of miR-29b. (D) Relative expression of miR-29b in the human cholangiocarcinoma cell line QBC939 and in human intrahepatic biliary epithelial cells (HIBEC). The values presented are means ± SD. *P<0.05 and **P<0.01 compared to the normal tissues or HIBEC cells, as determined by analysis of Student’s t-test.